RESUMO
INTRODUCTION: To measure the cost expenditure associated with renal cyst surveillance, we examined renal cyst surveillance patterns at our institution and the associated surplus cost of unindicated imaging. METHODS: Patients with a renal cyst diagnosis between January 2017 and June 2018 were identified and their respective clinical and imaging data were reviewed for surveillance patterns. Unindicated renal cyst followup was defined by the Radiographic Society of North America and Canadian Urological Association. Total unnecessary expenditures from ultrasound, computerized tomography and magnetic resonance imaging were calculated using cost of services provided by FAIRHealth Consumer®. Univariate and multivariable analyses were performed with statistical significance defined as p <0.05. RESULTS: A total of 1,100 patients were identified, with a random sample of 292 selected for analysis. Of these patients 271 were diagnosed with Bosniak I and II renal cysts. Overall 52 (19%) of these patients underwent unindicated imaging, which totaled 60 ultrasound, 19 computerized tomography and 5 magnetic resonance imaging. A total superfluous cost of $347,501 was calculated when extrapolating to the entire nephrology cohort. Multivariable analysis showed higher unindicated imaging for Bosniak II renal cysts compared to Bosniak I renal cysts (OR 3.2, 95% CI 1.6-6.3, p <0.001) and decreased surveillance imaging for African American compared to Caucasian patients (OR 0.29, 95% CI 0.13-0.59, p <0.001). CONCLUSIONS: Among patients diagnosed with Bosniak I and II renal cysts, unnecessary surveillance imaging was associated with higher hospital costs. Adherence to strict renal imaging guidelines for renal cysts can significantly reduce unnecessary expenditures, patient anxiety and patient harm.
RESUMO
PURPOSE: To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). METHODS: The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature. RESULTS: When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases). Improved survival and QOL with moderate toxicity risk are associated with docetaxel/prednisone. For asymptomatic/minimally symptomatic men, improved survival with unclear QOL impact and low toxicity are associated with sipuleucel-T. For men who previously received docetaxel, improved survival, unclear QOL impact, and moderate to high toxicity risk are associated with cabazitaxel/prednisone. Modest QOL benefit (without survival benefit) and high toxicity risk are associated with mitoxantrone/prednisone after docetaxel. No benefit and excess toxicity are observed with bevacizumab, estramustine, and sunitinib. RECOMMENDATIONS: Continue androgen deprivation (pharmaceutical or surgical) indefinitely. Abiraterone acetate/prednisone, enzalutamide, or (223)Ra should be offered; docetaxel/prednisone should also be offered, accompanied by discussion of toxicity risk. Sipuleucel-T may be offered to asymptomatic/minimally symptomatic men. For men who have experienced progression with docetaxel, cabazitaxel may be offered, accompanied by discussion of toxicity risk. Mitoxantrone may be offered, accompanied by discussion of limited clinical benefit and toxicity risk. Ketoconazole or antiandrogens (eg, bicalutamide, flutamide, nilutamide) may be offered, accompanied by discussion of limited known clinical benefit. Bevacizumab, estramustine, and sunitinib should not be offered. There is insufficient evidence to evaluate optimal sequences or combinations of therapies. Palliative care should be offered to all patients.